Summary
79 / 100 · Bulios Score
What speaks for it
- Earnings per share grew by 28% a year over the last 3 years.
- Out of every 100 USD of revenue, 18 USD is left as net profit.
- It earns 25 USD a year on every 100 USD of invested capital.
- The share price is below the Bulios Fair Price.
What to watch
- Earnings per share swing sharply from year to year.
Bulios Scoring describes a company's quality and track record, not its future return. A high score is not a buy signal. Learn more
Score in detailPrice
Is it expensive?
Looks cheapBulios Fair Price is an estimate of a stock's fair value from the Bulios valuation model. It is an input for your own analysis, not investment advice. How does it work?
Today you pay 13.7 USD for 1 USD of yearly profit. Over the last five years it was 17.3 USD on average.
Valuation in detailIs it growing?
Yes, fastRevenue (USD)
Diluted EPS (USD)
- Analyst estimate
Revenue grew by 13% a year over 5 years. Over the last 3 years it grew by 19% a year. Earnings per share grew by 28% a year over the last 3 years.
Growth in detailDoes it make money?
Very wellWhere 100 USD of revenue goes
- Cost of sales 69 USD
- Research and development 4.3 USD
- Sales and administration 10 USD
- Taxes and other -0.9 USD
- Net profit 18 USD
Net profit, industry median (Medical - Instruments & Supplies) 8.1 USD
Out of every 100 USD of revenue, 18 USD is left as net profit.
Profitability in detailIs it financially healthy?
YesRepaying all its debt would take 2.6 years of free cash flow. Its debt is larger than its cash.
Financial health in detailDoes it pay a dividend?
NoIt pays no dividend.
Dividends in detailWhat do analysts expect?
Mildly positive- Buy 1
- Hold 0
- Sell 0
No analyst has published a price target.
100% of the analysts recommend buying.
Analysts in detailWhat does it earn on?
Fiscal year 2013By product
- Non Warranty Repairs 100%
By region
- North America 80%
- Europe 19%
- Other 1.1%
Non Warranty Repairs brings in 100% of revenue.
Segments in detail